Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 120

Results For "Development"

2928 News Found

Biostar Pharma receives FDA approval Utidelone Injectable Phase 2/3 clinical trial for cell lung cancer
Drug Approval | June 20, 2023

Biostar Pharma receives FDA approval Utidelone Injectable Phase 2/3 clinical trial for cell lung cancer

This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable


Astellas and Cullgen enter inks agreement to advance innovative targeted protein degraders
News | June 19, 2023

Astellas and Cullgen enter inks agreement to advance innovative targeted protein degraders

Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses


USFDA approves Roche’s Columvi for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma
Drug Approval | June 19, 2023

USFDA approves Roche’s Columvi for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma

Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma


Nanoform and Celanese demonstrate enhanced drug delivery through smaller implants
News | June 19, 2023

Nanoform and Celanese demonstrate enhanced drug delivery through smaller implants

The increased drug load enabled by the nanoformed particles also allows smaller implants with sustained release properties to be developed.


Laurus Labs signs MOA with IIT Kanpur for novel gene therapy assets
Biotech | June 19, 2023

Laurus Labs signs MOA with IIT Kanpur for novel gene therapy assets

Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets


Merck completes acquisition of Prometheus Biosciences
News | June 17, 2023

Merck completes acquisition of Prometheus Biosciences

Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions


Pembrolizumab + Trastuzumab and chemotherapy met primary endpoint as first line of treatment for GEJ
News | June 17, 2023

Pembrolizumab + Trastuzumab and chemotherapy met primary endpoint as first line of treatment for GEJ

Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma


Health Ministry to prepare National Action Plan on AMR 2.0
Policy | June 17, 2023

Health Ministry to prepare National Action Plan on AMR 2.0

Convergent action on AMR identified as an important area of intervention


SMi discloses £6 million seed funding round, bolsters team with new C-suite hire
News | June 15, 2023

SMi discloses £6 million seed funding round, bolsters team with new C-suite hire

Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics


Airnov to showcase HDPE bottle range at upcoming CPHI China
News | June 15, 2023

Airnov to showcase HDPE bottle range at upcoming CPHI China

The new range of HDPE bottles is compliant with US FDA, EU regulations and Chinese DMF registration for use in dry pharmaceutical applications